Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors.

Rebecca A Haeusler | Kirsten Hartil | Bhavapriya Vaitheesvaran | Isabel Arrieta-Cruz | Colette M Knight | Joshua R Cook | Helene L Kammoun | Mark A Febbraio | Roger Gutierrez-Juarez | Irwin J Kurland | Domenico Accili
Nature communications | 2014

Insulin integrates hepatic glucose and lipid metabolism, directing nutrients to storage as glycogen and triglyceride. In type 2 diabetes, levels of the former are low and the latter are exaggerated, posing a pathophysiologic and therapeutic conundrum. A branching model of insulin signalling, with FoxO1 presiding over glucose production and Srebp-1c regulating lipogenesis, provides a potential explanation. Here we illustrate an alternative mechanism that integrates glucose production and lipogenesis under the unifying control of FoxO. Liver-specific ablation of three FoxOs (L-FoxO1,3,4) prevents the induction of glucose-6-phosphatase and the repression of glucokinase during fasting, thus increasing lipogenesis at the expense of glucose production. We document a similar pattern in the early phases of diet-induced insulin resistance, and propose that FoxOs are required to enable the liver to direct nutritionally derived carbons to glucose versus lipid metabolism. Our data underscore the heterogeneity of hepatic insulin resistance during progression from the metabolic syndrome to overt diabetes, and the conceptual challenge of designing therapies that curtail glucose production without promoting hepatic lipid accumulation.

Pubmed ID: 25307742

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: DK63608
  • Agency: NIDDK NIH HHS, United States
    Id: 3R37DK058282
  • Agency: NHLBI NIH HHS, United States
    Id: K99 HL111206
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK045024
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK058132
  • Agency: NIDDK NIH HHS, United States
    Id: DK020541
  • Agency: NIDDK NIH HHS, United States
    Id: DK57539
  • Agency: NIDDK NIH HHS, United States
    Id: R37 DK058282
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK058282
  • Agency: NHLBI NIH HHS, United States
    Id: HL111206
  • Agency: NIDDK NIH HHS, United States
    Id: P60 DK020541
  • Agency: NIDDK NIH HHS, United States
    Id: DK58282
  • Agency: NIDDK NIH HHS, United States
    Id: DK45024
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK063608
  • Agency: NHLBI NIH HHS, United States
    Id: R00 HL111206
  • Agency: NIDDK NIH HHS, United States
    Id: DK58132
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK020541
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK057539

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions